Shares of Becton, Dickinson and Company (BDX), popularly known as BD, have gained 0.9% since Jul 10, after the company announced reduced availability of blood culture vials due to issues with its supplier. The rise could be likely due to immediate measures taken by the company to mitigate this supply disruption, including leveraging its manufacturing expertise and collaborating with the FDA. The FDA issued a letter last week to healthcare providers highlighting the supply shortage, underscoring the critical role of blood culture testing in diagnosing and treating infections. The shortage will affect the ability of healthcare providers to efficiently diagnose infections, prompting BD to take immediate actions to ensure continuity of patient care and minimize any potential impact. More on the News BD is manually allocating BD BACTEC blood culture vials to mitigate the impact on patient care due to a supply shortage. The company is providing its supplier with its manufacturing expertise, using air shipments and modifying manufacturing schedules for rapid production to address any shortage. The company is also collaborating with the FDA to review all potential options to mitigate delays in supply. It has also planned to restart production at its former supplier of glass vials to help fill the intermittent gap in supply. The company has advised customers to prioritize vial use based on clinical needs, following guidelines from the Infectious Disease Society of America and the World Health Organization. While BD does not anticipate a significant financial impact from this issue, it is fully focused on restoring the supply of blood culture vials to normal levels. A Recent Development Earlier this month, BD introduced the BD Rhapsody Single Cell ATAC-Seq Assay, a groundbreaking tool for single-cell analysis. This new technology allows scientists to examine the epigenome of individual cells, providing insights into the chemical marks on DNA that influence disease mechanisms. By adding an epigenomic layer to their analyses, researchers can better understand how environmental factors affect DNA and cell function, advancing the study of diseases like cancer. Price Performance Shares of BD have declined 7.3% so far this year against the industry's 3.7% rise. The S&P 500 has witnessed an 18.2% rise in the same time frame. Zacks Investment Research Image Source: Zacks Investment Research Zacks Rank & Key Picks Currently, BD carries a Zacks Rank #3 (Hold). Some top-ranked stocks in the broader medical space are Quest Diagnostics (DGX), Universal Health Services UHS and Dexcom DXCM. Quest Diagnostics, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 5.20%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.67%. Quest Diagnostics shares have gained 3.2% compared with the industry’s 10.9% rise so far this year. Universal Health Services, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 15.20%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 8.12%. Universal Health Services has gained 17.5% compared with the industry's 10.2% rise so far this year. DexCom, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 22.90%. DXCM’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 34.10%. DexCom’s shares have declined 17.8% compared with the industry's 1.3% decrease so far this year Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Becton, Dickinson and Company (BDX):Free Stock Analysis Report Quest Diagnostics Incorporated (DGX):Free Stock Analysis Report Universal Health Services, Inc. (UHS):Free Stock Analysis Report DexCom, Inc. (DXCM):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...